<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
Oliver Sartor, Christian la Fougère, Markus Essler, Samer Ezziddin, Gero Kramer, Jörg Ellinger, Luke T. Nordquist, John Sylvester, Giovanni Paganelli, Avivit Peer, Martin Bögemann, Jeffrey Meltzer, Per Sandström, Frank Verholen, Daniel Y. Song
Abstract
We analyzed real-world clinical outcomes of sequential alpha-/beta-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). <b>Methods:</b> We assessed safety and overall survival in 26 patients who received lutetium-177–prostate-specific membrane antigen ligand (<sup>177</sup>Lu-PSMA) following radium-223 in the ongoing non-interventional Radium-223 alpha Emitter Agent Safety Study in mCRPC popUlation for long-teRm Evaluation (REASSURE; NCT02141438). <b>Results:</b> Patients received radium-223 for a median 6 injections and subsequent <sup>177</sup>Lu-PSMA for a median 3.5 months (≥4th therapy in 69%). The median time between radium-223 and <sup>177</sup>Lu-PSMA treatment was 8 months (range 1–31). Grade 3 hematologic events occurred in 9/26 patients (during or after <sup>177</sup>Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 months from radium-223 start and 13.2 months from <sup>177</sup>Lu-PSMA start. <b>Conclusion:</b> Although the small sample size precludes definitive conclusions, these preliminary data, especially <sup>177</sup>Lu-PSMA treatment duration, suggest feasibility of <sup>177</sup>Lu-PSMA use after radium-223 in this real-world setting.